COMP <GO>
PAHC vs LLY // GROSS PROFIT MARGIN
Phibro Animal Health Corporation (Class A) (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: PAHC 3
— LLY 10
▲ GROSS PROFIT MARGIN LEADER: LLY
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
gross-margins
30.90%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
gross-margins
83.64%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAHC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAHC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 30.90% | 83.64% | -52.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 32.36% | -22.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.2x | 36.4x | -17.22 | PAHC | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 2.30% | +2.78 | PAHC | /fcf-yield <GO> |
| Operating Margin | 8.50% | 40.21% | -31.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 31.90% | -28.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 27.40% | 45.51% | -18.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 0.49% | +0.74 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.87 | 9.29 | -6.42 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 66.6 | -9.70 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | 26.3x | +1.25 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.58B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAHC REV | LLY REV | PAHC GROSS % | LLY GROSS % | PAHC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.30B | $65.18B | 30.9% | 83.0% | $80.1M | $16.81B |
| FY 2024 | $1.02B | $45.04B | 30.8% | 81.3% | $87.6M | $8.82B |
| FY 2023 | $977.9M | $34.12B | — | 79.3% | $13.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAHC // BETA —
LLY // BETA 0.51